NASDAQ$PSNL
Personalis Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Reported a 24% increase in revenue compared to Q1 2022 and announced several collaborations and partnerships to advance personalized cancer testing and MRD measurement.
Personalis, Inc. reported a 24% increase in revenue for the first quarter of 2023, driven by growth in pharma tests and enterprise sales. The company is focused on expanding its presence in the MRD space, enabling personalized cancer vaccine development, and supporting biopharmaceutical customers with clinical trials.
- Revenue grew 24% year-over-year, demonstrating execution against strategic focus.
- Pharma tests, enterprise, and other customers revenue increased by 35% compared to Q1 2022.
- Collaborations announced with Cancer Research UK, University College London, and AstraZeneca to utilize NeXT Personal assay.
- Partnership established with Criterium and ABRCC for a clinical trial to validate NeXT Personal assay in early-stage TNBC.
Headline financials
Revenue & EPS history
Personalis · Revenue · Quarterly
$18.9M
Revenue by segment
Personalis · $18.9M total across 4 segments · Q1 2023
- Enterprise sales$9.46M—50.1%
- Pharma tests and services$6.33M—33.6%
- Population sequencing$3.01M—15.9%
- Other$64K—0.3%
Forward guidance
Personalis expects total company revenue of $16 million to $17 million for the second quarter of 2023. For the full year 2023, Personalis expects total company revenue in the range of $68 million to $72 million and a net loss of approximately $103 million.
Tailwinds
- Total company revenue of $16 million to $17 million for Q2 2023
- Revenue from pharma tests, enterprise sales, and other customers of $13 million to $14 million for Q2 2023
- Revenue from population sequencing of approximately $3 million for Q2 2023
- Total company revenue in the range of $68 million to $72 million for full year 2023
- Revenue from pharma tests, enterprise sales, and all other customers in the range of $59 million to $63 million for full year 2023
Headwinds
- Revenue from population sequencing of approximately $9 million for full year 2023
- Net loss of approximately $103 million for full year 2023
- Cash usage of approximately $75 million for full year 2023
- Second quarter revenue is expected to be lower than Q1 2023
- Full year revenue growth is expected to slow down compared to 2022
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2023
+1.0%
Avg return
Earnings day
+1.5%
Avg return
5 days after
+1.5%
Avg return
30 days after
59%
16 / 27 earnings
Positive
+19.9%
Q1 2025
Best reaction
-23.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.2% | -0.7% | +76.6% | |
| Q4 2025 | +0.6% | -1.1% | -29.8% | |
| Q3 2025 | -12.3% | -1.1% | +9.5% | |
| Q1 2025 | +19.9% | +27.5% | +30.3% | |
| Q4 2024 | -2.4% | +5.9% | -14.6% | |
| Q3 2024 | -23.4% | -12.8% | -26.4% | |
| Q2 2024 | +7.2% | +34.7% | +67.8% | |
| Q1 2024 | +4.4% | -2.5% | -14.6% | |
| Q4 2023 | +3.3% | +16.0% | -0.7% | |
| Q3 2023 | +10.4% | -3.8% | +39.6% | |
| Q2 2023 | +4.7% | +7.9% | -17.9% | |
| Q1 2023 | +4.5% | +3.2% | -6.4% | |
| Q4 2022 | -7.2% | -5.3% | -18.2% | |
| Q3 2022 | -1.5% | -15.3% | +4.7% | |
| Q2 2022 | +10.6% | +11.1% | -21.4% | |
| Q1 2022 | -7.2% | -24.8% | -34.1% | |
| Q4 2021 | +12.2% | +11.0% | -14.4% | |
| Q3 2021 | +2.6% | -5.4% | -38.9% | |
| Q2 2021 | +10.2% | +4.1% | +12.4% | |
| Q1 2021 | -0.6% | -9.9% | -4.3% | |
| Q4 2020 | -11.1% | -10.8% | -36.3% | |
| Q3 2020 | +0.1% | -0.3% | +13.6% | |
| Q2 2020 | -2.4% | -3.7% | -4.7% | |
| Q1 2020 | +4.6% | +7.2% | +27.6% | |
| Q4 2019 | +17.5% | +27.5% | +52.8% | |
| Q3 2019 | +0.2% | -12.7% | +0.3% | |
| Q2 2019 | -15.6% | -6.2% | -11.6% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro